MedTrace Logo

Anthocyanins as Dementia Prevention?

NCT03419039 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2020-09-03

No results posted yet for this study

Summary

The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

Conditions

Interventions

DIETARY_SUPPLEMENT

Anthocyanins

Medox tablet containing 80 mg anthocyanins.

DIETARY_SUPPLEMENT

Placebo

Identically appearing capsules.

Sponsors & Collaborators

  • Helse Stavanger HF

    lead OTHER_GOV

Principal Investigators

  • Dag Aarsland, MD., PhD. · Helse Stavanger HF

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-05
Primary Completion
2021-02-15
Completion
2021-02-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03419039 on ClinicalTrials.gov